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Summary 
This review provides an update on the current clinical and preclinical understanding of 
chemotherapy induced peripheral neuropathy (CIPN). The overview of the clinical syndrome, 
includes a review of its assessment, diagnosis and treatment. CIPN is caused by several widely-
used chemotherapeutics including paclitaxel, oxaliplatin, bortezomib. Severe CIPN may require 
dose reduction, or cessation, of chemotherapy, impacting on patient survival. While CIPN often 
resolves after chemotherapy, around 30% of patients will have persistent problems, impacting on 
function and quality of life. Early assessment and diagnosis is important, and we discuss tools 
developed for this purpose. There are no effective strategies to prevent CIPN, with limited 
evidence of effective drugs for treating established CIPN. Duloxetine has moderate evidence, with 
extrapolation from other neuropathic pain states generally being used to direct treatment options 
for CIPN. The preclinical perspective includes a discussion on the development of clinically-
relevant rodent models of CIPN and some of the potentially modifiable mechanisms that have been 
identified using these models. We focus on the role of mitochondrial dysfunction, oxidative stress, 
immune cells and changes in ion channels from summary of the latest literature in these areas. 
Many causal mechanisms of CIPN occur simultaneously and/or can reinforce each other. Thus, 
combination therapies may well be required for most effective management. More effective 
treatment of CIPN will require closer links between oncology and pain management clinical teams 
to ensure CIPN patients are effectively monitored. Furthermore, continued close collaboration 
between clinical and preclinical research will facilitate the development of novel treatments for 
CIPN. 
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Introduction 
Neuropathic pain, defined as " Pain caused by a lesion or disease of the somatosensory nervous 
system” is a challenging clinical problem, with up to 8% of the population suffering from moderate to 
severe pain. 1, 2, 3. Neuropathic pain may have an even greater impact on patients than other chronic 
pain syndromes with affected individuals rating their quality of life as "worse than death" , on the EQ-
5D, a validated quality of life measure 3. Unfortunately, many modern chemotherapeutic agents can 
cause both acute and chronic peripheral neuropathy - chemotherapy induced peripheral neuropathy 
(CIPN) 4. During oncological treatment, the severity of the acute syndrome may require reducing the 
dose of chemotherapy or even stopping it, with potential impact on tumour control and survival.  
 
Chemotherapy-induced painful neuropathy (CIPN) is a major dose-limiting side effect of several 
first-line chemotherapeutic agents 5-10. CIPN is a challenging and complex pain syndrome that we 
have no effective preventive and limited treatment options for currently. CIPN can have a major 
and prolonged impact on quality of life for patients. As oncological treatments have advanced, 
cancer survival has increased significantly, with many patients either being cured of cancer or 
living for many years with cancer. Given the prevalence of the common cancers (e.g. breast, 
ovarian, colorectal) these chemotherapeutics counteract, CIPN affects several million patients 
worldwide each year. CIPN also places a significant economic burden on patients due to workloss 
and the healthcare system due to its prevalence 11.  Effective collaboration between preclinical and 
clinical researchers is needed to translate improved understanding of the underlying mechanisms 
into development of effective preventive and treatment strategies 12. This review aims to provide an 
overview of the clinical syndrome, its assessment, diagnosis and treatment, and how our improved 
understanding of underlying mechanisms contribute to this. While there are, multiple factors 
contributing to CIPN, we will focus on the role of mitochondrial dysfunction, oxidative stress, 
immune cells and changes in ion channels in CIPN rodent models. 
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CIPN: The Clinical Syndrome 
CIPN usually presents as a typical "glove and stocking" neuropathy. Patients describe a range of 
predominantly sensory symptoms including numbness, parathesia, ongoing/spontaneous pain, 
hypersensitivity to mechanical and/or cold stimuli in their hands and feet. In more severe cases, loss 
of vibration sense and joint position sense contribute to the impact on function. Autonomic and motor 
dysfunction may also occur. Patients can have significant difficulty in essential daily functions 
including difficulty in fine finger movement such as buttoning clothing, and unsteady gait (numbness, 
loss of joint position sense); pain on walking (mechanical hypersensitivity); inability to remove items 
from a fridge, or exacerbation in cold weather (cold hypersensitivity). CIPN may present acutely, 
during chemotherapy, such as is commonly seen with platinum based compounds 13. It may also 
occur after treatment has finished - a phenomenon known as "coasting" -where either mild 
neuropathy worsens, or new CIPN develops. This is challenging for oncologists, as there is no 
indication during chemotherapy to allow dose modification in order to reduce CIPN 14. Pain and 
sensory abnormalities can persist for months or years following the cessation of chemotherapy 5, 15, 
16. Therefore, patients may well be cancer-free, but suffering a debilitating neuropathy evoked by 
their cancer treatment.  
 
Peripheral neuropathy has been long associated with established drugs such as platinum agents 
(e.g. oxaliplatin), vinca alkaloids (e.g. vincristine), and taxanes (e.g. paclitaxel). However, newer, 
more targeted drugs, such as bortezomib, eribulin and ixabepilone 4, 17 are also associated with 
significant incidence of peripheral neuropathy. All of these chemotherapeutics have different 
mechanisms by which they evoke their anti-mitotic effects e.g. perturbation of microtubule dynamics, 
DNA cross-linking, proteasome inhibition. Whether all these drugs evoke neurotoxicity by similar 
mechanisms remains to be determined. 
 
Prevalence and risk factors for CIPN 
The prevalence of CIPN varies between different agents, with reported rates varying from 19% to 
more than 85% 18. While the agent and dose used is an important determining factor, there is no 
doubt that the lack of a gold standard agreed assessment tool impacts on reported rates of CIPN 19. 
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A systemic review and meta-analysis of CIPN incidence and prevalence with paclitaxel, bortezomib, 
cisplatin, oxaliplatin, vincristine or thalidomide (solo or combination) treatment demonstrated the 
persistence of this disorder 20. CIPN was observed in 68.1%, 60%, and 30% of patients, within the 
first month, at 3 months, and at ≥6 months, respectively, after cessation of chemotherapy, when 
looking at chemotherapy as a whole. While type of chemotherapy is important, at least part of the 
variability in reported prevalence was due to differences in the timing of assessment 20.   
 
A number of possible risk factors have been identified, including genetic factors, although there is a 
need for more systematic evaluation of potential contributory factors.  A number of single nucleotide 
polymorphisms potentially associated with CIPN have been identified through Genome Wide 
Association Studies. Proteins with a range of functions have been identified, including axon 
outgrowth, sodium channels and neuronal apoptosis 21-25. Studies of clinical risk factors are limited, 
often with small sample sizes. From the available data for CIPN, a history of neuropathy prior to 
starting chemotherapy (eg diabetic), impaired renal function with reduced creatinine clearance, and 
a history of smoking may all increase risk of developing CIPN. The cumulative dose of chemotherapy 
is well recognised as a major risk factor, with growing interest in the effect of levels of circulating 
growth factors or other biological markers as a means of early identification of quantifiable risk factors 
20. 
 
Assessment and diagnosis of CIPN 
There is currently no widely accepted, standardized assessment approach for diagnosis of CIPN 
per se. There are a number of guidelines on assessment and diagnosis of neuropathic pain in 
general, which may be useful in CIPN 26-28.  Onset of symptoms during, or shortly after, 
chemotherapy is normally described, often affecting feet first, then with impairment of sensation in 
fingers and hands.  If patients describe abnormalities in sensation, or these are detected on clinical 
examination, then CIPN should be suspected. Early identification allows treatment decisions about 
continuation, or not, of chemotherapy to be better informed, as well as allowing initiation of anti-
neuropathic agents, if appropriate 29, 30.  
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Accurate understanding of the epidemiology of CIPN, early identification and treatment of the 
clinical problem and evaluation of new treatments would all be improved by a standardized 
approach.  The aim of the CI-PeriNomS Study Group was to assess reproducibility and validity of 
existing measures, and if necessary develop a simple and reproducible assessment for CIPN to try 
and meet this need 31. A number of the tools available for assessing CIPN have been robustly 
assessed and show good reliability and validity (see table 1) 32. From this, abnormalities in 
monofilament testing and vibration perception may be useful in identifying CIPN 33-35. Quantitative 
sensory testing (QST) is recommended as part of neuropathic pain assessment, and may have 
clinical utility in early assessment of CIPN. 26, 27. There is some evidence that there are baseline 
QST deficits in cancer patients even prior to starting chemotherapy, that may predispose them to 
developing CIPN, raising the possibility that the cancer process itself may be involved 36. Sensory 
abnormalities, for example with raised detection threshold of small bumps of variable quantified 
sizes ("bumps test"), with an associated reduction in Meissner's Corpuscles counts were found in 
patients before chemotherapy. Furthermore, long-term outcome for pain and sensory disturbances 
during chemotherapy was more pronounced in patients with baseline sensory deficits compared to 
patients who presented without deficits 37, 38.  
 
In patients with established CIPN QST abnormalities indicate deficits in A-beta fibe (altered touch 
detection to monofilaments, and altered bumps test), A-delta fibre (impaired sharpness detection) 
and C-fibre (pin prick) function. The importance of these findings is that classes of primary afferent 
fibers show differential impairments, indicating that the underlying mechanisms are particular to 
nerve fiber types as opposed to a non-specific toxicity 16, 39, 40. Changes in QST have been shown 
to be associated with alterations in epidermal nerve fibre density, occurring in a pattern that 
matches the distribution of symptoms, such that the lowest counts are in the painful area, but get 
progressively higher moving proximal where the symptoms change to numbness and then to no 
complaint. The decrease in ENF density matches the QST data in these patients in that they had 
elevated pain and sharpness detection thresholds in the fingers and palm 16, 41 . Currently, routine 
clinical assessment of patients undergoing chemotherapy often does not include measurement of 
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sensory function. Based on the current evidence, simple tests of vibration sense or light touch may 
be useful clinical tools, that merit further study.  
  
Prevention and treatment of CIPN 
Many RCTs have investigated potential therapies for the prevention of CIPN development or 
reversal of established CIPN. However, clinical practice guidelines from the American Society of 
Clinical Oncology (ASCO) following a systematic review of this literature did not recommend any 
agent for the prevention of CIPN. There have been a number of small trials of agents to prevent 
CIPN developing, ranging from acteyl-l-carnitine to vitamin E, with no evidence of major benefit 30. 
Treatment of CIPN is mainly based on evidence from other chronic neuropathic pain conditions, 
rather than specifically targeting underlying mechanisms in CIPN.  A comprehensive review of the 
evidence base for all types of neuropathic pain found some overestimation of the treatment effect 
(~10%), with combined numbers needed to treat (NNTs) being modest (table 2). In the ASCO 
guidelines, specifically about CIPN, a moderate recommendation was made for duloxetine in the 
treatment of established CIPN. Generally, whilst evidence for agents used in other neuropathic 
pain syndromes (as shown in table 2) is lacking for CIPN, it is still reasonable to try them, after 
appropriate discussion with the patient.  There was also a weak recommendation for a topical  gel 
containing baclofen (10mg), amitripyline (40mg) and ketamine (20mg), based on one study 30, 42. 
As preventative/curative treatment options for CIPN are currently limited, dose reduction or 
cessation of chemotherapy is often associated with the emergence of symptoms of neuropathy 43. 
Thus, CIPN potentially impacts on both the quality of life and survival of cancer patients. There are 
a number of areas of therapeutic interest arising from preclinical studies. 
 
Animal models of CIPN 
Developing rodent models of CIPN which replicate all the symptoms that patients report is somewhat 
challenging because numbness, tingling and ongoing pain all rely on verbal report from the patient. 
Thus, most studies have focussed on measuring evoked pain-like behaviours as has been the case 
for preclinical studies with other chronic pain models. Investigations into novel measures of 
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spontaneous pain in CIPN rats are ongoing and paclitaxel-induced deficits in burrowing behaviour 
and voluntary wheel running were recently observed (data shown at NeupSIG 2017). Rat and mice 
models of CIPN have been reported following administration of different chemotherapeutics 
including paclitaxel, docetaxel, vincristine, cisplatin, oxaliplatin, bortezomib 44, 45. Initial work 
investigating the neurotoxicity associated with paclitaxel involved direct application of paclitaxel to 
peripheral nerves resulting in degeneration and specific aggregation of microtubules 46-48. However, 
the relevance of such local application of chemotherapy to understanding mechanisms of CIPN that 
are evoked by systemic administration is limited due to the high endoneurial concentration.  In later 
studies, rodent models of paclitaxel-induced painful neuropathy were developed using systemic 
paclitaxel administered via intravenous or intraperitoneal routes e.g. 49, 50. In fact, most of the dosing 
regimens (reviewed in 44, 45) utilized to create rodent CIPN models involve intermittent systemic 
administration to mimic cycles of chemotherapy as opposed to daily dosing.  
 
Typically, most models of CIPN involve the solo administration of a given chemotherapeutic in the 
absence of tumour load. However, there are reports using a rat model possessing an implanted 
subcutaneous tumour with combined paclitaxel and cisplatin treatment 51, 52. Animal health must be 
considered when employing rodent models of CIPN for ethical reasons and practical feasibility. Pain-
like behaviours cannot be accurately assessed if rodents are ill due to systemic toxicity and thus 
lethargic/unresponsive to hind paw stimulation. Although rodent models of CIPN with a tumour could 
be considered as more clinically relevant, the practical/ethical issues of this should not to be 
underestimated. In addition, as chemotherapy is often received after surgical removal of the tumour 
to eliminate possible micro-metastases, modelling CIPN through chemotherapy administration alone 
is a valid approach. For new preclinical investigations, the use of established intermittent dosing 
schedules to generate CIPN models is encouraged as much as possible. Wide adoption of the same 
dosing schedules across different laboratories would further understanding of causal mechanisms 
of CIPN and enhance reproducibility. 
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CIPN models typically display sensory symptoms such as mechanical allodynia, mechanical 
hyperalgesia, cold allodynia, and in some reports, heat hyperalgesia. tOxaliplatin-induced peripheral 
neuropathy is associated with an acute cold/mechanical hypersensitivity within hours of 
administration and a chronic neuropathy. Both syndromes can be replicated in rats and mice at a 
range of systemic doses 45. Studies with paclitaxel demonstrated that the cumulative dose 
administered affects both the integrity of peripheral nerves and the behavioural symptoms evoked. 
Systemic administration of low-doses of paclitaxel (<10mg/kg cumulative dose) did not markedly 
affect neural microtubule structure or cause aggregation 53 as observed following epineural 
administration 46-48. Following low dose paclitaxel, neurodegeneration was not evident mid-axon or 
in the DRG 53, however there is a loss of intraepidermal nerve fibres (IENFs) 54, 55. Greater degrees 
of degeneration in peripheral nerves and the DRG were caused by larger cumulative doses of 
paclitaxel (<16mg/kg) in a dose-dependent manner 49, 56-58. The dose-dependent effects of paclitaxel 
administration have also been observed in patients, where the incidence and severity of neuropathic 
signs and symptoms increased relative to increasing cumulative doses of paclitaxel 59. Paclitaxel-
evoked behaviours in rodents are also dose-dependent. Mechanical and cold allodynia without motor 
deficit are observed at low doses 50, 60, 61. In contrast, heat hypoalgesia and motor deficit is reported 
at high doses, which is likely indicative of significant neurodegeneration 49, 62-64. Collectively, these 
studies indicate that pain associated with CIPN is not necessarily a result of marked peripheral nerve 
degeneration.  
 
Role of mitochondrial dysfunction in CIPN 
Over the last decade, research has identified mitochondrial dysfunction has a significant contributory 
factor in CIPN. The first preclinical evidence identified swollen and vacuolated mitochondria in both 
myelinated axons and C-fibres in peripheral sensory nerves following systemic paclitaxel 53. 
Paclitaxel-induced changes in neuronal mitochondria, correlated to the development and 
maintenance of paclitaxel-induced pain syndrome i.e. present prior to and during paclitaxel-induced 
pain, but absent when the pain syndrome had resolved 53. These low dose paclitaxel-induced 
mitochondrial changes in C-fibres and myelinated axons have since been confirmed by many groups 
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65-70. Paclitaxel increased the incidence of swollen/vacuolated mitochondria in dorsal root C-fibres 
and A-fibres 66 and the DRG 70-72, but not in the ventral root or Schwann cells 66. There is also 
evidence for mitochondrial dysfunction from the clinical literature. Two case reports show electron 
micrographs of sensory axons containing swollen, vacuolated mitochondria in sural nerve biopsies 
from patients with chemotherapy-induced neuropathy evoked by paclitaxel 73 and docetaxel 74. 
Swollen/vacuolated mitochondria have also been observed in C-fibres and A-fibres of rat models of 
oxaliplatin-induced painful neuropathy 75 and bortezomib-induced painful neuropathy 76. The 
presence of swollen mitochondria does not indicate the nature of mitochondrial dysfunction evoked. 
This can be determined through assays of mitochondrial function. Significant decreases in complex 
I-stimulated and complex II-stimulated respiration in sciatic nerves from paclitaxel-, oxaliplatin and 
bortezomib-treated rats were observed prior to, and during chemotherapy-induced pain behaviour 
76, 77. Recent data discussed at NeupSIG 2017 demonstrates the maximal respiration and spare 
reserve capacity (the respiratory ability of the cell to overcome stress) were significantly decreased 
in DRG neurons from paclitaxel-treated rats prior to pain onset 78. During paclitaxel-induced pain, 
these OXPHOS-driven respiratory deficits in DRG neurons resolved, yet DRG neurons become more 
glycolytic in their function and preferentially switch to glycolysis from OXPHOS. The switch to 
glycolysis may be an adaptive mechanism to produce less ROS and prevent apoptosis through the 
increased pentose phosphate pathway activity and elevated glutathione peroxidase levels 79. These 
paclitaxel-evoked changes in bioenergetics are also associated with decreased ATP. Prior to and 
during paclitaxel-induced pain, less ATP was present in DRG neurons in situ 78, yet deficits in ATP 
production in peripheral nerves are only observed during maximally stimulated conditions 77, 80. There 
was no change in the bioenergetic status of DRG neurons of paclitaxel-treated rats when the pain 
syndrome had resolved 78 further indicating the contribution of these factors to the development and 
maintenance of paclitaxel-induced pain.  
 
Several studies have examined in vivo pharmacological modulation of the mitochondrial electron 
transport chain (ETC) in CIPN models 81-83. Differential effects of specific complex inhibition have 
been observed (reviewed in 84) which may be explained by route of drug administration, inhibitor in 
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question or time point examined post chemotherapy administration. For example, antimycin A 
(complex III inhibitor) significantly inhibited the development of paclitaxel-induced mechanical 
hypersensitivity when given before and during paclitaxel administration, but had no effect when given 
after paclitaxel administration 83. Other pharmacological reagents that directly interact with 
mitochondria and their function in different ways have shown their potential to alleviate CIPN 53, 69, 70, 
85-87. Acetyl-L-carnitine (ALC) is involved in free fatty acid oxidation and acts as an antioxidant. 
Prophylactic ALC administration prevented the development of paclitaxel-induced mechanical 
hypersensitivity 53; paclitaxel-evoked increase in swollen/vacuolated mitochondria in C-fibres 65; and 
paclitaxel-, oxaliplatin and bortezomib-evoked compromises in mitochondrial respiration in sciatic 
nerves 76, 77. Despite promising preclinical data 88-91 and an open-label phase II trial of CIPN patients 
92, a placebo-controlled RCT reported prolonged ALC treatment was associated with more severe 
paclitaxel-evoked neurotoxicity in breast cancer patients 93. TRO19622 /Olesoxime, which directly 
binds to mitochondria (at the mPTP), attenuated chemotherapy-induced mechanical hypersensitivity 
and IENF loss, but had no effect on paclitaxel-induced spontaneous discharge in C- and A-fibres 85, 
86. Inhibition of mitochondrial fission significantly attenuated oxaliplatin-induced mechanical 
hyperalgesia 87. Pifithrin-μ, an inhibitor of mitochondrial p53 accumulation, prevented development 
of paclitaxel- and cisplatin-induced mechanical hypersensitivity70. Pifithrin-μ also prevented 
paclitaxel-evoked mitochondrial changes in sensory neurons and IENF loss with evidence of 
enhancement of paclitaxel’s anti-tumour effects 70. Similarly, minoxidil was recently shown to prevent 
paclitaxel-evoked nociceptive behaviour and mitochondrial changes in sensory neurons 
accompanied with augmentation of paclitaxel’s anti-tumour action 69.  
Role of oxidative stress in CIPN  
Mitochondria are a major source of reactive oxygen species (ROS) and increased ROS production 
can be a consequence of mitochondrial dysfunction. However, there are other cellular sources of 
ROS and reactive nitrogen species (RNS). Evidence for ROS involvement in neuropathic pain 
dates back to the 1990s e.g. 94 and ROS/RNS have multiple effects on neuronal excitability 
(reviewed in 95). The role of oxidative stress in CIPN has been examined in vivo using 
pharmacological reagents that scavenge ROS. PBN, a non-specific ROS scavenger, inhibited the 
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development of paclitaxel-induced mechanical hypersensitivity 96, 97; reversed established 
paclitaxel-induced mechanical & cold hypersensitivities 96, 97; and bortezomib-induced mechanical 
hypersensitivity 98. High doses of TEMPOL, a superoxide dismutase mimetic, inhibited the 
development and maintenance of paclitaxel-induced mechanical hypersensitivity 97, 99, but was 
ineffective on cold allodynia 97. Another SOD mimetic, MnL4, inhibited oxaliplatin-induced 
mechanical and cold hypersensitivities 100. Peroxynitrite decomposition catalysts have been shown 
to reverse established paclitaxel-induced mechanical hypersensitivity 101 and to also prevent the 
development of mechanical hypersensitivity induced by paclitaxel, oxaliplatin and bortezomib 80, 101. 
Novel mitochondria-targeted antioxidants have also been evaluated. SS-31 attenuated oxaliplatin-
induced cold & mechanical hypersensitivities 102. MitoVitE attenuated the development of 
paclitaxel-induced mechanical hypersensitivity 103.  
 
Other studies have measured ROS/RNS levels within the nociceptive system of CIPN models in 
vivo to understand the cellular basis/location of oxidative stress during CIPN. Increased RNS 
production was indicated in the spinal cord of paclitaxel-treated rats 101. In addition, increased ROS 
and RNS levels were seen in lumbar DRG following chronic oxaliplatin treatment in mice 102. Data 
discussed at NeupSIG 2017 showed how oxidative stress is linked to the development, 
maintenance and resolution of CIPN. ROS levels were elevated in superficial spinal neurons and 
non-peptidergic (IB4+) DRG neurons, in vivo, prior to the onset of paclitaxel-induced pain 
behaviour 79, suggesting ROS is an initiating factor. The preferential elevation of ROS in IB4+ 
neurons could suggest a direct mechanism by which TRPA1 channels, known neuronal ROS 
sensors and predominantly expressed on IB4+ DRG neurons 104, contribute to paclitaxel-induced 
pain 105, 106. To understand how ROS was managed endogenously, we also examined the activity 
of different antioxidant enzymes in the DRG and peripheral sensory nerves during the timecourse 
of paclitaxel-induced painful neuropathy. Enhanced activity of mitochondrial and cellular 
endogenous antioxidant enzymes in the DRG and peripheral nerves was observed, however this 
was inadequate and delayed in its onset leading to excessive ROS in peripheral sensory axons 79. 
Others have demonstrated an impaired mitochondrial antioxidant response following paclitaxel, 
13 
 
oxaliplatin and bortezomib 80. Collectively these in vivo preclinical studies suggest that 
mitochondrial ROS is causal to the development and maintenance of CIPN. 
 
Role of immune cells in CIPN  
In addition to effects on mitochondria and the generation of oxidative stress, chemotherapy agents 
also engage the innate immune system to induce peripheral neuropathy. A key mediator in this is 
the toll-like receptors (TLR). These are transmembrane proteins that normally function to detect 
various pathogens, TLR4 specialized to detect bacterial pathogens and TLR3 specialized to detect 
viral pathogens by example. TLR4 is also activated by several chemotherapeutics107. TLR4 and its 
immediate downstream signals are increased in the DRG of rats with paclitaxel-induced 
hyperalgesia; and this hyperalgesia can be prevented by co-treating animals with TLR4 antagonists 
during chemoterapy108, 109. Similarly, mice with a genetic knockout of either TLR4 or TLR3 fail to 
develop hyperalgesia following treatment with cisplatin110. It appears that a key result of TLR4 
activation by chemotherapeutics is to increase pro-inflammatory cytokine expression in the 
peripheral and central nervous systems.  The C-C motif chemokine ligand 2 (CCL2, also called 
monocyte chemoattractant protein 1 or MCP1) and its receptor CCR2 are increased small DRG 
neurons that appear to be nociceptors and in spinal astrocytes in rats with paclitaxel related CIPN. 
111. Gene knockdown or knockout of CCR2 or use of a chemical CCR2 antagonist reduced 
neuropathic pain in mice112 113. 
 
Macrophages are normally not found in large numbers in the DRG, yet the immediate result of the 
paclitaxel-induced increase in CCL2 in the DRG is a marked increase in these cells within the DRG 
within a few days of treatment114. These macrophages have a pro-inflammatory phenotype that 
results in increased levels of Interleukin-1 (IL-1) and Tumor necrosis factor alpha (TNFα) in the DRG. 
A number of studies have shown that pro-inflammatory cytokines such as these produce 
hyperalgesia to both thermal and mechanical stimuli115, 116. This occurs by a number of mechanisms. 
IL-1 and TNFα act on both spinal and DRG neurons to lower their threshold of activation, a process 
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termed sensitization, and to induce spontaneous discharges117, 118, 119. TNFα specifically also 
suppresses the signalling of spinal GABA neurons leading to central disinhibition of pain signalling 
120. IL-1 and TNFα, as well as IL-6 also increase the release of bradykinin, serotonin, and histamine 
that further augments pro-inflammatory processes 121, 122.  Increased production and release of IL-1, 
TNFα and CCL2 is a shared effect following administration of several chemotherapeutics including 
paclitaxel 123, cisplatin 124 and vincristine125. Importantly given that both neurons and glial cells 
express receptors for these cytokines and can also produce these following activation this 
mechanism has the potential to become self-sustaining126. 
 
Increased levels of IL-1, TNFα and CCL2 in the DRG and spinal cord produce alterations in Schwann 
cells along peripheral axons, satellite cells in the DRG, and astrocytes in the spinal cord that further 
contribute to chemotherapy related hyperalgesia.  A constant observed following treatment with 
several different chemotherapy agents is that astrocytes show a down-regulation in the expression 
of glutamate transporters. These are key to clearing synaptically released glutamate and dysfunction 
in this process leads to hyperexcitability of spinal neurons. As referenced above, the activation of 
Schwann cells leads to further release cytokines IL-1 and TNFα 127 128, 129 (see more below), but also 
leads to the extirpation of these cells from peripheral axons 56, resulting in reduced action potential 
propagation as well as longer term reduced protection and nourishment of nerve fibers. Satellite cells 
in the DRG react similarly to Schwann cells when exposed to chemotherapy agents130 resulting in 
pro-apoptotic stress in DRG neurons. Satellite cells also increase their expression of gap junctions 
following chemotherapy treatment. Although the exact basis is unclear this appears to further 
promote pain signalling given that gap junction blockers produce an analgesic effect in CIPN mice 
131. An unusual aspect of glial response in the spinal cord is that astrocytes, but not microglia become 
activated in CIPN 132, 133, 134. In many other types of neuropathic pain a primary role is assigned to 
microglia that does not appear to be involved in CIPN. Like in Schwann cells, inhibitors of gap 
junctions in astrocytes results in reduced hyperalgesia in CIPN, an a similar anti-hyperalgesic 
response is produced using the glial inhibitor minocycline 135, 136. 
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Changes in ion channels in CIPN 
The net result of the activation of innate immune responses in the DRG and spinal cord is the 
induction of hyperexcitability and ectopic spontaneous activity in both peripheral and spinal neurons. 
These, in turn are due to alterations in neuronal ionic homeostasis as revealed by ion channel 
microarray 137. By example, given the primacy of Na+ ions in generating electrical activity in neurons, 
it is almost expected that alterations in voltage-gated sodium channels occur in CIPN. Recent work 
by our group that will be presented at NeuPSIG 2017 shows that the expression and function of the 
voltage-gated sodium channel Nav1.7 is markedly increased in DRG neurons following paclitaxel 
treatment and contributes directly to the development of ectopic spontaneous activity in nociceptors 
(Li et al, 2017, submitted). As well, prolonged opening in voltage-gated Na+ channels is produced 
by oxalate, a metabolite of oxaliplatin that results in lowered activation threshold and ectopic firing 
in DRG neurons 138, 139. Enhanced activity in sodium channels would appear to reflect the increased 
peripheral axonal excitability seen prior to symptom expression in patients 140, 141. Beyond the spinal 
cord and DRG, increased expression of voltage gated sodium channels is also found in forebrain 
regions following paclitaxel treatment 142. A caveat to this latter observation is that forebrain changes 
in sodium channels would be secondary to alterations occurring elsewhere given the poor 
penetrance of paclitaxel to the CNS. These preclinical observations are supported by clinical findings 
in that voltage-gated sodium channel blockers, such carbamazepine, that have found success in 
treating some 143, but not all neuropathic pain patients 144.  
 
A second ion channel that is key in resulting neuronal excitability is that for potassium. Alterations in 
K+ channel function have been noted at several levels of the neuraxis in CIPN. By example, K+ 
channels are down-regulated in the cortex and in primary afferent neurons of rats with oxaliplatin 
CIPN 145, 146; and in the DRG of rats with paclitaxel-related CIPN 137. In congruity with the observed 
changes in Na+ and K+ channels just noted others have reported an increased expression in 
hyperpolarization-activated channels (HCNs) that are permeable to both ions in CIPN 147. 
Mathematical modelling of the consequences of the observed changes in Na+ and K+ channels 
indicates that these account well for the observed hyper-excitability in nociceptors that occurs in 
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oxaliplatin CIPN 148. The therapeutic potential of targeting K+ channels in CIPN is supported by the 
observation that the K+ channel opener, retigabine, reduced signs of hyperalgesia in mice with 
cisplatin-related CIPN 149.  
 
Voltage-gated calcium channels are key in regulating synaptic transmission and so not surprisingly 
also implicated in the hyper-excitability in CIPN. DRG neurons show increased levels of voltage-
gated calcium channel mRNA following paclitaxel treatment in mice 150. Antagonists to voltage-gated 
calcium channels including gabapentin and ethosuximide were both effective in reducing signs of 
hyperalgesia in rodents with paclitaxel- and vincristine-induced CIPN60, 151. Consistent with these 
findings is that paclitaxel treatment was shown to alter calcium metabolism in primary afferent fibers 
152 and treatment with minoxidil reversed this effect while also ameliorating the behavioural signs of 
paclitaxel-related CIPN 69. 
 
A large group of non-selective cation channels specifically localized in nociceptors that are 
involved in CIPN symptoms is the transient receptor potential (TRP) channels. Specifically, the 
TRP vanilloid 1 (TRPV1) and the TRP ankyrin 1 (TRPA1) subgroups have been implicated in 
CIPN-related pain. TRPV1, commonly also known as the receptor for capsaicin (the active 
ingredient in hot chili peppers) is physiologically activated by protons, heat above 42oC, and 
endogenous lipids produced during inflammation (for review, see153). The sensation produced by 
activation of TPV1 are exactly those that are experienced by CIPN patients16, 41, in cutaneous 
nociceptors TRPV1 produces burning154, while in deep tissue nociceptors TRPV1 produces deep 
aching pain 155, 156. Paclitaxel activates and sensitizes the function of TRPV1 and TRPV1 
antagonists produce analgesia in paclitaxel-related CIPN 157. Similarly treatment with either 
bortezomib or cisplatin produced an increases in TRPV1 expression in DRG and spinal cord in 
mice 158, 159. Paclitaxel directly interacts with the TRPV1 channel to produce both and acute 
facilitation of signalling and also produces a long-term alteration of channel desensitization. The 
acute interaction has also been validated in human DRG neurons  160. Parallel studies suggest that 
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oxaliplatin also sensitizes the TRPV1 and that this effect is mediated by the G-protein coupled 
receptor G2A 161. 
 
TRP ankyrin 1 (TRPA1) is often colocalized with TRPV1 and is activated by formalin, allyl 
isothiocyanate, and acrolein; and by temperatures below 170C 162. Given that activation of TRPA1 is 
activated by noxious cold stimuli in animals163, it has been suggested that this channel may mediate 
the acute hypersensitivity to cold observed in patients following oxaliplatin treatment. Preclinical 
studies using oxaliplatin appear to support this view164, 165 and appear to also be generalizable to 
paclitaxel-induced cold hyperalgesia 105. Preclinical studies have further detailed that chronic 
symptoms of CIPN may be mediated by chemotherapy-induced activation of proteinase-activated 
receptors (PARs) that activate phospholipase C, protein kinase A and protein kinase C epsilon that 
then sensitize TRPA1 as well as TRPV1 and TRPV4 channels, respectively 106. Further support for 
a role of TRPA1 in CIPN is that receptor deficient mice were shown to be resistant to both oxaliplatin- 
and bortezomib-related CIPN167. Interestingly, in the context of previous discussion on oxidative 
stress, TRPA1 mediates neuropathic pain in trigeminal neurons downstream to the activation of 
macrophages/monocytes and their generation of oxidative stress 168. Yet, human psychophysical 
studies suggest that even though noxious cold activates TRPA1 in rodents this may not be true in 
humans166, indicating that perhaps one final TRP channel may have an important role. 
 
The transient receptor potential melastatin 8 (TRPM8) channel is activated by mild cool stimuli 
between 25 and 28oC and chemically by menthol 169 and has been implicated as analgesic when 
activated in some nerve injury models 170. Some have suggested that TRPM8 could mediate cold-
hyperalgesia in humans in CIPN. Yet, others have shown that topical menthol produces analgesia 
in paclitaxel CIPN patients 171 and this has been supported in a recent proof-of-concept study 172. 
Other receptors subtypes including A3 adenosine receptors 173, 5HT2A receptors 174, 175, sigma-1 
receptors68 and mGluR5 receptors 176 have been implicated in CIPN and could prove potential 
avenues for new treatments.  
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Conclusions  
Preclinical models of CIPN can provide vital insight into the neurotoxic mechanisms that initiate and 
maintain CIPN. Compared to other chronic pain conditions, differential analgesic effects are 
observed in both CIPN patients and rodent models suggesting different causal mechanisms for 
CIPN. Many of the causal mechanisms of CIPN described in this review occur simultaneously and/or 
can reinforce each other. It seems likely therefore, that effective future developments may use 
combination therapies to either prevent development of CIPN where possible, or direct effective 
treatment for CIPN. There are very few clinical trials of combination therapies in any type of 
neuropathic pain, and it may be that to detect a clinically significant effect, we need to reconsider 
how clinical trials for neuropathic pain are designed 177-179. An additional complexity in trials of CIPN 
is the effect of cancer on the pathophysiology of the pain systems: we do need to address how to 
translate preclinical models of single morbidities (such as CIPN) to the often complex co-morbidities 
that are seen in our aging population. More effective treatment of CIPN will require closer links 
between oncology and pain management clinical teams to ensure CIPN patients are effectively 
monitored. Furthermore, continued close collaboration between clinical and preclinical research will 
facilitate the development of novel treatments for CIPN. 
 
Figure Legends 
Figure 1: Summary of the pathophysiological events contributing to chemotherapy-induced 
peripheral neuropathy (CIPN) as highlighted in this review. The most common agents provoking 
CIPN are shown in the bubble in A and the sites of action for these compounds are indicated by 
the arrows. The structures are also labeled in A while in B the changes occurring in these 
structures with CIPN are summarized. Reproduced with permission from Boyette-Davis JA, 
Walters ET, Dougherty PM, Mechanisms involved in the development of chemotherapy induced 
peripheral neuropathy. Pain Manag. 5 (4): 285-296, 2015. 
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Table 1: Some of the tools used for assessing CIPN 
Tool Comments Reference
s 
 National Cancer Institute-Common Toxicity Criteria (NCI-CTC) Grade 0-3 
depending on 
degree of 
sensory loss; 
deep tendon 
reflexes; 
parathesia 
180, 181 
Total Neuropathy Score clinical version (TNSc) Includes 
assessment of 
neuropathy 
signs and 
symptoms, with 
limited 
information 
about pain; 
some 
quantitative 
sensory testing 
(vibration  
threshold, 
standardized 
monofilaments) 
182 
modified Inflammatory Neuropathy Cause and Treatment 
(INCAT) group sensory sumscore (mISS) 
Includes 
vibration  
threshold, 
standardized 
monofilaments, 
plus 2 point 
discrimination 
183 
European Organization for Research and Treatment of Cancer 
(EORTC) QLQ-C30  
Not specific for 
CIPN, but gives 
a reliable 
measure of the 
impact of CIPN, 
and can allow 
comparison with 
other cancer 
populations. 
184 
CIPN20 quality-of-life measures Assesses 
different 
components, 
including 
sensory, 
autonomic and 
motor 
symptoms;  
185, 186 
 
Table 2. Combined NNTs for agents used in treatment of neuropathic pain (based on results 
from 187). NNT = number-needed-to-treat; CI= confidence interval; SNRI= serotonin, 
noradrenaline reuptake inhibitor 
Drug NNT (95% CI) Strength of recommendation for 
use 
SNRIs (mainly 
Duloxetine) 
6.4 (5.2-8.4)  
Strong, first line 
Pregabalin 7.7 (6.5-9.4) 
Gabapentin 7.2 (5.9-9.21) 
Tri-cyclic anti-
depressants 
3.6 (3.0-4.4) 
Lidocaine patches 5% Low quality evidence  
Weak, second line Capsaicin patch 8% 10.6 (7.4-19.0) 
Tramadol 4.7 (3.6-6.7) 
Strong opioids 4.3 (3.4-5.8) Weak, third line 
Botulinum toxin A Only very small 
studies  
Weak, third line, specialist use only 
 
 
